Clinical trials: Eye Diseases, Hereditary
Diabetes Mellitus Associated With Genetic Syndrome, Wolfram Syndrome
GLP Analogs for Diabetes in Wolfram Syndrome Patients
Wolfram syndrome, also referred to as DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy and deafness) is a genetic syndrome characterized by beta-cell dysfunction and apoptosis leading to diabetes, neurodegeneration…
- Trial name
- NCT01302327
- Testing
- Exenatide
- Sponsor
- Hadassah Medical Organization
Gyrate Atrophy
Gyrate Atrophy of the Choroid and Retina
Gyrate atrophy is a rare hereditary disease of the eye's retina (the layer of light-sensitive tissue that lines the inside of the eyeball) and choroid (a vascular layer of tissue behind the retina).
- Trial name
- NCT00001166
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Eye Institute (NEI)
STGD1, Stargardt Disease 1
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease
- Trial name
- DRAGON II (NCT06388083)
- Testing
- Tinlarebant
- Where
- 18 sites in United States, Japan and 1 more
- Volunteers
- 60 people
- Sponsor
- Belite Bio, Inc
Macular Degeneration, Age-related Maculopathies
Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration
The study will involve approximately 40 subjects aged 55 or above who have exudative age-related macular degeneration (wet AMD).
- Conditions
- Macular Degeneration, Age-related Maculopathies, Age-related Maculopathy, Maculopathies,Age-related
- Trial name
- AMD (NCT01494805)
- Testing
- rAAV.sFlt-1, Control (ranibizumab alone)
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- Lions Eye Institute, Perth, Western Australia
Early Age Related Macular Degeneration (Disorder)
Evaluation of R:GEN as Intervention in Subjects With Early Stages of AMD for Safety and Exploratory Efficacy Outcomes
The purpose of this study is to assess the safety and tolerability of the R:GEN Laser System in subjects with the early stages of age-related macular degeneration.
- Trial name
- NCT04776031
- Testing
- R:GEN Laser System
- Where
- Australia
- Volunteers
- 31 people
- Sponsor
- Lutronic Vision, Inc
Hermansky-Pudlak Syndrome (HPS)
Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome
Hermansky-Pudlak Syndrome (HPS) is an inherited disease which results in decreased pigmentation (oculocutaneous albinism), bleeding problems due to a platelet abnormality (platelet storage pool defect), and storage of an abnormal…
- Trial name
- NCT00001456
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Graves Ophthalmopathy
Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.
This study is a randomized, controlled, multi-center clinical study, the purpose is to evaluate the efficacy and safety of rapamycin combined with methylprednisolone in the treatment of moderate to severe active GO.
- Trial name
- NCT05532072
- Testing
- Rapamycin, Methylprednisolone
- Where
- China
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Benign Prostatic Hyperplasia
Optilume™ BPH Catheter System in Men With Symptomatic BPH
PINNACLE is a prospective, multi-center, randomized control clinical trial to establish the safety and efficacy of the Optilume™ BPH Catheter System in the treatment of benign prostatic hyperplasia (BPH)
- Trial name
- PINNACLE (NCT04131907)
- Testing
- Optilume BPH Catheter System
- Where
- 21 sites in United States, Canada
- Volunteers
- 162 people
- Sponsor
- Urotronic Inc.
Leber Hereditary Optic Neuropathy
REALITY LHON Registry
This study is a multi-country retrospective and cross-sectional observational study of affected LHON subjects, based on retrospective subjects' medical chart abstractions and cross-sectional administration of patient-reported…
- Trial name
- REALITY (NCT03295071)
- Testing
- Patient-reported outcomes (PROs)
- Where
- 11 sites in United States, France and 3 more
- Volunteers
- 44 people
- Sponsor
- GenSight Biologics
Fuchs Endothelial Corneal Dystrophy
A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)
A study to assess the safety and efficacy of K-321 in participants with FECD after simultaneous cataract surgery and descemetorhexis.
- Trial name
- NCT05826353
- Testing
- Ripasudil
- Where
- 43 sites in United States, Canada and 4 more
- Volunteers
- 110 people
- Sponsor
- Kowa Research Institute, Inc.
Retinopathy of Prematurity (ROP)
Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)
The main purpose of this study is to evaluate the long-term efficacy and safety outcomes following short-term exposure to rhIGF-1/rhIGFBP-3 versus standard neonatal care in Study ROPP-2008-01 (NCT01096784).
- Trial name
- PEDAL (NCT02386839)
- Testing
- rhIGF-1/rhIGFBP-3
- Where
- 16 sites in United States, Italy and 4 more
- Volunteers
- 76 people
- Sponsor
- Shire
Behcet Syndrome
Pan-immune-inflammation Value (PIN) in Behçet's Disease and Its Correlation With Disease Activity
Behçet's disease (BD) is a systemic vasculitis affecting both small and large blood vessels in the venous and arterial systems. It is a multiorgan disease with various manifestations, including mucocutaneous, articular, ocular…
- Trial name
- NCT06729112
- Testing
- pan immune inflammation value
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assiut University
Stargardt's Disease
Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration
Primary Objective: To evaluate the long-term safety and tolerability of SAR422459 in patients with Stargardt's Macular Degeneration. Secondary Objective: To assess: Safety Biological activity
- Trial name
- NCT01736592
- Testing
- Long term follow up in all patients who received SAR422459 in previous study TDU13583
- Where
- 2 sites in United States, France
- Volunteers
- 27 people
- Sponsor
- Sanofi
Thyroid Eye Disease
An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab
This is a clinical trial to evaluate the safety and efficacy of veligrotug (LUMVOA™) in participants with moderate to severe TED who previously received and responded to an initial course of teprotumumab treatment but…
- Trial name
- NCT07832136
- Testing
- veligrotrug (LUMVOA™)
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Viridian Therapeutics, Inc.
Retinopathy of Prematurity
Incidence of Hypoxia During Intravitreal Anti-VEGF (Vascular Endothelial Growth Factor) Injections for Retinopathy of Prematurity (ROP) Under Topical Anesthesia
Purpose: To evaluate the incidence and severity of hypoxia and address a genuine evidence gap focusing on intraprocedural hypoxia during bedside intravitreal ranibizumab injection for retinopathy of prematurity (ROP), an area…
- Trial name
- NCT07701759
- Testing
- ranibizumab
- Where
- Saudi Arabia
- Volunteers
- 74 people
- Sponsor
- Minia University
Dry Eye Disease (DED), Graves Ophthalmopathy
Effect of Low-Level Light Therapy on Ocular Surface Parameters in Patients With Graves Disease
This prospective, interventional, randomized, controlled, double-blind clinical study evaluates the effect of Low-Level Light Therapy (LLLT) delivered by a polychromatic periocular mask (Eye-light®️) versus a sham device in…
- Trial name
- LLLT-Graves (NCT07332988)
- Testing
- Low Light Level therapy
- Where
- Romania
- Volunteers
- 30 people
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Atopic Dermatitis
Ophthalmological Adverse Events of Tralokinumab in AD
Atopic dermatitis (AD) is a skin disease characterised by xerosis, pruritus and erythematous plaques. It is common in children (10 to 20%) with an increasing prevalence (multiplied by 2 in 20 years) and begins to develop at 3…
- Trial name
- TRALO-Oeil (NCT05682976)
- Where
- 11 sites in France
- Volunteers
- 100 people
- Sponsor
- Nantes University Hospital
Choroiditis, Iridocyclitis
Evaluation and Treatment of Patients With Inflammatory Eye Diseases
This study offers evaluation and treatment for patients with inflammatory eye diseases, such as uveitis. The protocol is not designed to test new treatments; rather, patients will receive current standard of care treatments.
- Conditions
- Choroiditis, Iridocyclitis, Iritis, Retinal Disease
- Trial name
- NCT00006188
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- National Eye Institute (NEI)
Corneal Dystrophy, Macular Dystrophy
The Efficacy of Hyperemesis Gravidarum on Macular Thickness, Corneal Thickness and Intraocular Pressure in Pregnancy
Aim Physiological changes in intraocular pressure as well as in the cornea and macula may occur during pregnancy. In the literature, there are limited data on ocular findings in hyperemesis gravidarum.
- Conditions
- Corneal Dystrophy, Macular Dystrophy, Hyperemesis Gravidarum - Severe
- Trial name
- NCT05927740
- Testing
- Optic coherence tomography
- Where
- Turkey (Türkiye)
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Batman Training and Research Hospital
Graves Disease, Graves Ophthalmopathy
Impact of Intravenous Methylprednisolone Treatment on Blood Pressure
Hypertension is common side effect of Cushing Syndrome (CS): in patients with endogenous CS and those treated with glucocorticosteroids (GCs). The impact of the intravenous GCs therapy on blood pressure (BP) remains unclear.
- Conditions
- Graves Disease, Graves Ophthalmopathy, Hypertension, Blood Pressure
- Trial name
- NCT03590080
- Testing
- Methylprednisolone
- Volunteers
- 32 people
- Sponsor
- Medical University of Warsaw
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.